When the fungal pathogen is unknown, consider AmBisome® as an option when treating the next IFI – in vitro data demonstrates that AmBisome® is effective against rare and difficult-to-treat infections, including azole-resistant strains.9-12
When the fungal pathogen is unknown, consider AmBisome® as an option when treating the next IFI – in vitro data demonstrates that AmBisome® is effective against rare and difficult-to-treat infections, including azole-resistant strains.9-12
AmBisome® demonstrates in vitro fungicidal activity against major Aspergillus species, including A. fumigatus and A. flavus.19
AmBisome® demonstrates in vitro fungicidal activity against a multitude of Candida species, including C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis and C. lusitaniae.10
In the fight against mucormycosis, AmBisome® demonstrates in vitro fungicidal activity against Mucorales.10
AmBisome® demonstrates efficacy in HIV/AIDS patients with acute cryptococcal meningitis and in vitro fungicidal activity against cryptococcus neoformans*10,41
AUBMC: American University of Beirut Medical Center.
Date of preparation: April 2022. Job code: IHQ-AMB-0429.